Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT01429402
Other study ID # 98-2237C
Secondary ID
Status Recruiting
Phase Phase 3
First received September 4, 2011
Last updated September 6, 2011
Start date July 2000
Est. completion date August 2013

Study information

Verified date August 2011
Source Chang Gung Memorial Hospital
Contact n/a
Is FDA regulated No
Health authority Taiwan: Institutional Review Board
Study type Interventional

Clinical Trial Summary

Botulinum toxin type A (Botox; Allergan, Inc., Irvine, Calif) is widely used for facial rejuvenation and many other medical indications. It induces chemodenervation through its action on the presynaptic neuron, preventing release of acetylcholine, which leads to functional denervation of striated muscle for 2 to 6 months after injection. The use of botulinum toxin injection to reduce the facial scar is logical because this could reduce the tensile distracting force of the upper lip caused by the orbicularis oris muscle pull. Tollefson has demonstrate that botulinum toxin injection has decrease lip tension after primary lip repair in 3 children at 3-6 months of age The main aim of this randomized trial is to compare whether post-operative peri-surgical-injection of botulinum toxin into bilateral orbicularis oris muscles can improve scar formation for both primary and secondary cleft lip surgery.


Description:

This is a randomized controlled trial primarily designed to compare the scarring after primary and secondary cleft lip repair using post-operative botulinum toxin injection. There will be 4 main groups in this study:-

1. Study group I: For primary lip surgery, immediately after primary lip repair will received botulinum toxin injection (1-2U/kg, at 25U/mL) into the bilateral aberrant oriented orbicularis ocuris muscle via 4 superficial injection site (Tollefson TT 2006).

2. Study group II: For revision lip surgery, immediately after revision lip surgery 3 injection of 2.5U of botulinum toxin with a distance of 0.5 cm from each injection and operative wound are injected over both sides of upper lip in a adult on the operation room.

3. Control group I : Similar amount (in C.C.) of normal saline will be injected after primary lip surgery at 3 months of age.

4. Control group II: Similar amount (in C.C.) of normal saline will be injected after revision lip surgery (secondary cleft lip repair).

4. ELIGIBILITY 4.1 Inclusion criteria for the primary lip repair group (i) Baby born with cleft lip who will receive primary lip repair at 3 months of age (iii) Written informed consent given by parent/guardian.

4.2 Inclusion criteria for the secondary lip repair group (i) Adult > 16 years old. (ii) Moderate to severe secondary cleft lip and/or nose deformity that warrants corrective surgery.

(iii) Written informed consent given by parent/guardian/patient.

4.3 Patient numbers: 60 for primary lip repair and 60 for secondary lip repair

4.31 Sample size calculation: 10 consecutive patient selected from our OPD on march 2009. Vancouver Scar Scale means 4.6 with SD 1.264911 (rage 3-7). If the study group with improvement of 1 is clinical significant, giving power 0.8 with the same SD, the sample size calculated will be 26.

Using Terason Ultrasound (capacity of measured 1/100 cm or 1/10 mm) the scar width mean is 1.13 mm with SD .6201254. If the study group with improvement of 0.5 mm as clinical significant, giving the power of 0.8 with the same SD, the sample size calculated will be 25.

We will use 30 patients for each group.

4.41 Exclusion criteria for primary lip repair

1. Combined other craniofacial anomalies

2. Without permission of parent/guardian, without signed informed consent by parent/guardian.

4.42 Exclusion criteria for the secondary lip repair

1. Less than 15 years old

2. Mild secondary cleft lip and / or nose deformity that does not warrant corrective surgery.

3. Without written informed consent.

4. Without permission of parent/guardian, the patient signed the consent himself.

5. Botulinum Toxin injection 5.1 For Study group I: Injections are placed into the orbicularis oris muscle 5 mm adjacent to the scar and the vermilion border on each side of the operative wound (A total of 3 injections per side making a total of 6 injections per patient). 1-2U/kg (total dosage for baby) and 2.5 U (adult ) of botulinum toxin (Botox; allergen, Inc., Irvine, Calif) will be used for each injection. A total dosage of 15 U (for adult) will be injected into each patient.

For control group a similar amount of Normal saline will be injected.

6. STUDY VISITS AND ASSESSMENTS 6.1 Registration and Randomization (i) Confirmation of eligibility (ii) Information Sheet (iii) Written informed consent (iv) Registration of baby and adult into study and randomization (v) Scheduling of patient for botox injection immediately after surgery.

6.2 Follow-up Assessments 6.2.1 Vancouver scar scale (Sullivan T 1990) measures pigmentation, vascularity, pliability and scar height on the postoperative 6 month F/U.

Ultrasonography measurement of the scar (Fong SS 1997)

For both primary and secondary lip surgery, the patient will receive postoperative follow up during 1wk, 1mo, 3mo, 6mo. On the 1st week postoperative follow up, the stitches will be removed, 3M taping will be placed over the wound to reduce surface tension and minimize the scar formation. On the 6th mo follow up, a lay person will assess the scar using the Vancouver scar and a plastic surgeon will use ultrasonography to measure the scar.

The Independent T-Student test will be used to analyze the statistical significance between the two groups.

Photographic measurement of scar The scar width of the patient's picture at 6 month after surgery will be measured using photoshop CS3 extended. One ruler will be placed on the patient's lip before taken the photo. Then the scar width could be measured.


Recruitment information / eligibility

Status Recruiting
Enrollment 120
Est. completion date August 2013
Est. primary completion date August 2010
Accepts healthy volunteers No
Gender Both
Age group 3 Months to 45 Years
Eligibility Inclusion Criteria:

Inclusion criteria for the primary lip repair group

- Baby born with cleft lip who will receive primary lip repair at 3 months of age

- Written informed consent given by parent/guardian.

Inclusion criteria for the secondary lip repair group

- Adult > 16 years old.

- Moderate to severe secondary cleft lip and/or nose deformity that warrants corrective surgery.

- Written informed consent given by parent/guardian/patient.

Exclusion Criteria:

- Those patient not fit inclusion criteria

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Drug:
Botulinum Toxin Type A
1-2U/kg, at 25U/mL, into the bilateral aberrant oriented orbicularis ocuris muscle via 4 superficial injection site; only once after surgery. No additional injection is needed
Botulinum Type A
b. Study group II: For revision lip surgery, immediately after revision lip surgery 3 injection of 2.5U of botulinum toxin with a distance of 0.5 cm from each injection and operative wound are injected over both sides of upper lip in a adult on the operation room just after surgery. (total dosage injected 15U)
Normal Saline
Similar amount (in C.C.) of normal saline as group I will be injected after primary lip surgery at 3 months of age.
Normal Saline
Similar amount (in C.C.) of normal saline as study group II will be injected after revision lip surgery (secondary cleft lip repair).

Locations

Country Name City State
Taiwan Chun Shin Chang Taoyuan

Sponsors (1)

Lead Sponsor Collaborator
Chang Gung Memorial Hospital

Country where clinical trial is conducted

Taiwan, 

References & Publications (8)

Gassner HG, Brissett AE, Otley CC, Boahene DK, Boggust AJ, Weaver AL, Sherris DA. Botulinum toxin to improve facial wound healing: A prospective, blinded, placebo-controlled study. Mayo Clin Proc. 2006 Aug;81(8):1023-8. — View Citation

Gassner HG, Sherris DA, Friedman O. Botulinum toxin-induced immobilization of lower facial wounds. Arch Facial Plast Surg. 2009 Mar-Apr;11(2):140-2. doi: 10.1001/archfacial.2009.3. — View Citation

Gassner HG, Sherris DA, Otley CC. Treatment of facial wounds with botulinum toxin A improves cosmetic outcome in primates. Plast Reconstr Surg. 2000 May;105(6):1948-53; discussion 1954-5. — View Citation

Larrabee WF Jr. Treatment of Facial Wounds with Botulinum Toxin A Improves Cosmetic Outcome in Primates. Plast Reconstr Surg. 2000 May;105(6):1954-1955. — View Citation

Lee BJ, Jeong JH, Wang SG, Lee JC, Goh EK, Kim HW. Effect of botulinum toxin type a on a rat surgical wound model. Clin Exp Otorhinolaryngol. 2009 Mar;2(1):20-7. doi: 10.3342/ceo.2009.2.1.20. Epub 2009 Mar 26. — View Citation

Sherris DA, Gassner HG. Botulinum toxin to minimize facial scarring. Facial Plast Surg. 2002 Feb;18(1):35-9. — View Citation

Tollefson TT, Senders CM, Sykes JM, Byorth PJ. Botulinum toxin to improve results in cleft lip repair. Arch Facial Plast Surg. 2006 May-Jun;8(3):221-2. — View Citation

Wilson AM. Use of botulinum toxin type A to prevent widening of facial scars. Plast Reconstr Surg. 2006 May;117(6):1758-66; discussion 1767-8. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Vancouver Scar scale Vancouver scar scale measures pigmentation, vascularity, pliability and scar height on the postoperative 6 month F/U. 6 month Yes
Secondary Ultrasonography scar measurement On the 6th mo follow up, ultrasonography to measure the scar width will be performed. 6 month Yes
Secondary Photographic measurement The scar width of the patient's picture at 6 month after surgery will be measured using photoshop CS3 extended. One ruler will be placed on the patient's lip before taken the photo. Then the scar width could be measured. 6 month Yes
See also
  Status Clinical Trial Phase
Recruiting NCT03646955 - Partial Breast Versus no Irradiation for Women With Early Breast Cancer N/A
Completed NCT01706848 - Celotres for Improvement in Wound Healing and Resulting Scar Consequences Following Suturing of a Wound N/A
Recruiting NCT01177358 - Botox in the Healing of Surgical Wounds of the Neck Phase 2
Terminated NCT01459666 - Forehead Scars Following Mohs Micrographic Surgery and Reconstruction for Skin Cancer Phase 4
Completed NCT00970671 - Treatment of Surgical Scars Using the Pulsed Dye Laser N/A
Recruiting NCT03561376 - Zinc Oxide Versus Petrolatum Following Skin Surgery Early Phase 1
Completed NCT05293652 - Effect of Hydrocortisone Iontophoresis Versus Hydrocortisone Phonophoresis On Post Surgical Scar N/A
Recruiting NCT03406143 - Evaluation of the Effect of CGF in Promoting Mechanical-stretch Induced in Vivo Skin Regeneration N/A
Completed NCT05527756 - Evaluation of the Cosmetic Outcomes of Totally Endoscopic Cardiac Surgery
Completed NCT02886988 - Early Postoperative Prevention and Treatment of Median Sternotomy Scars With Botulinum Toxin Type A Injection Phase 2/Phase 3
Completed NCT05618912 - Scar Appearance After Postoperative Hydrocolloid Dressing Versus Standard Petrolatum Ointment N/A
Recruiting NCT05408117 - Impact of Suture Type on Pigment Disturbances in Patients of Skin of Color N/A
Completed NCT04169438 - Pilot Study Investigating a Restorative Wound Care Cream Together With Petrolatum on Surgical Excisions N/A
Terminated NCT02520557 - An Exploratory Study of Genetic and Clinical Factors for Serious Skin Reactions Among Users of Eslicarbazepine Acetate
Not yet recruiting NCT04621994 - Cesarean Wound Closure: Dermabond Versus Steri Strips N/A
Withdrawn NCT03395678 - Acne Scarring in Skin of Color: Laser vs Microneedling N/A
Completed NCT02744950 - Comparison of Scar Results and Time for Closures of Scalp Defects Via Pulley Sutures or Layered Repairs N/A
Not yet recruiting NCT01005992 - Fractional Photothermolysis for the Treatment of Burn Scars Phase 1
Completed NCT04870008 - Aesthetic Outcome of Running Cuticular Suture Distance (2mm vs 5mm) N/A
Recruiting NCT04506255 - Silicone Taping for the Improvement of Abdominal Donor Site Scars N/A